These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 27556178)

  • 61. Concurrent chemoradiotherapy for organ function preservation in advanced patients with hypopharyngeal and laryngeal cancer.
    Kogashiwa Y; Yamauchi K; Nagafuji H; Matsuda T; Tsubosaka T; Tsutsumi T; Karaho T; Kohno N
    Oncol Rep; 2009 Nov; 22(5):1163-7. PubMed ID: 19787235
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment results and prognostic factors for advanced squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy.
    Taguchi T; Nishimura G; Takahashi M; Komatsu M; Sano D; Sakuma N; Arai Y; Yamashita Y; Shiono O; Hirama M; Sakuma Y; Ishitoya J; Hata M; Ogino I; Oridate N
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):837-43. PubMed ID: 23959463
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
    Abgral R; Le Roux PY; Keromnes N; Rousset J; Valette G; Gouders D; Leleu C; Mollon D; Nowak E; Querellou S; Salaün PY
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1839-47. PubMed ID: 22895863
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma.
    Li R; Ye L; Zhu Y; Ding H; Wang S; Ying H; Wu C; Zhou L; Wang X; Tian S
    Head Neck; 2022 Sep; 44(9):2018-2029. PubMed ID: 35915867
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin.
    Corry J; Bressel M; Fua T; Herschtal A; Solomon B; Porceddu SV; Wratten C; Rischin D
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):948-954. PubMed ID: 28483336
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Oncological and functional outcomes in T3 and T4 laryngeal cancer patients: choice for larynx preservation or total laryngectomy based on expected laryngeal function.
    Nobacht A; Meijer TWH; Oosting SF; van der Vegt B; Wedman J; Halmos GB; Plaat BEC
    J Laryngol Otol; 2024 Jun; 138(6):672-678. PubMed ID: 38235588
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Single-cycle induction chemotherapy for resectable advanced hypopharyngeal cancer.
    Nakashima T; Yasumatsu R; Asai K; Uryu H; Kogo R; Nakagawa T
    Int J Clin Oncol; 2017 Jun; 22(3):442-447. PubMed ID: 28062933
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.
    Kies MS; Haraf DJ; Athanasiadis I; Kozloff M; Mittal B; Pelzer H; Rademaker AW; Wenig B; Weichselbaum RR; Vokes EE
    J Clin Oncol; 1998 Aug; 16(8):2715-21. PubMed ID: 9704722
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
    Haddad R; O'Neill A; Rabinowits G; Tishler R; Khuri F; Adkins D; Clark J; Sarlis N; Lorch J; Beitler JJ; Limaye S; Riley S; Posner M
    Lancet Oncol; 2013 Mar; 14(3):257-64. PubMed ID: 23414589
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma.
    Teknos TN; Cox C; Barrios MA; Chepeha DB; Bradford CR; Fisher SG; Wolf GT
    Laryngoscope; 2002 May; 112(5):844-51. PubMed ID: 12150616
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer.
    Fung K; Lyden TH; Lee J; Urba SG; Worden F; Eisbruch A; Tsien C; Bradford CR; Chepeha DB; Hogikyan ND; Prince ME; Teknos TN; Wolf GT
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1395-9. PubMed ID: 16087298
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
    Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
    Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review.
    Winquist E; Agbassi C; Meyers BM; Yoo J; Chan KKW;
    J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):29. PubMed ID: 28376866
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Larynx preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck cancer. A long-term follow-up report.
    Karp DD; Vaughan CW; Carter R; Willett B; Heeren T; Calarese P; Zeitels S; Strong MS; Hong WK
    Am J Clin Oncol; 1991 Aug; 14(4):273-9. PubMed ID: 1713738
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience.
    Nguyen-Tan PF; Le QT; Quivey JM; Singer M; Terris DJ; Goffinet DR; Fu KK
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1172-80. PubMed ID: 11483326
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
    Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
    J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma.
    Prades JM; Lallemant B; Garrel R; Reyt E; Righini C; Schmitt T; Remini N; Saban-Roche L; Timoshenko AP; Trombert B; Guerrier B
    Acta Otolaryngol; 2010; 130(1):150-5. PubMed ID: 19449227
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial.
    Peng H; Chen L; Li WF; Guo R; Mao YP; Zhang Y; Guo Y; Sun Y; Ma J
    Cancer; 2017 May; 123(9):1643-1652. PubMed ID: 28001301
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
    Haddad R; Tishler R; Wirth L; Norris CM; Goguen L; Sullivan C; O'Donnell L; Li Y; Posner M
    Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):678-81. PubMed ID: 16785415
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma.
    Kim HR; Lee CG; Choi EC; Kim JH; Koh YW; Cho BC
    Head Neck; 2016 Apr; 38 Suppl 1():E1653-9. PubMed ID: 26890965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.